Sign in
Taking people in Puerto RicoPhase 2

Blood and marrow marker tests in acute myeloid leukemia and myelodysplastic syndrome

Tests blood and marrow markers in people with myeloid cancer.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
San Juan, Puerto RicoSee the 2 sitesAlso in 2 other countries, 358 sites
Trial code
Registry title
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Status
Recruiting
Phase
Phase 2
People taking part
2,000 people, planned
Started
18 Jun 2024
Expected to end
15 May 2029
Type of study
Interventional, 30 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Azacitidine
  • Best Practice
  • Biopsy Procedure
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Busulfan
  • Chest Radiography
  • Computed Tomography
  • Cytarabine
  • Daunorubicin
  • Daunorubicin Hydrochloride
  • Decitabine and Cedazuridine
  • Echocardiography Test
  • Emavusertib
  • Enasidenib
  • Epoetin Alfa
  • Fludarabine
  • Gemtuzumab Ozogamicin
  • Gilteritinib
  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Luspatercept
  • Melphalan
  • Multigated Acquisition Scan
  • Mutation Carrier Screening
  • Olutasidenib
  • Placebo Administration
  • Positron Emission Tomography
  • Quizartinib
  • Total-Body Irradiation
  • Venetoclax
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who may have newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Bone marrow and blood tests are used to assign them to a treatment study or standard care.

Age
18 years or older
Sex
All sexes can join
Disease stage
Suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has not been treated before. People with AML cannot have had earlier treatment for myeloproliferative neoplasms (MPN) or MDS.
Earlier treatment
No earlier anti-cancer treatment for AML or MDS. Hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide are allowed, for up to 1 month. Up to 1 g/m^2 of cytarabine is allowed for urgent cytoreduction.

Main reasons for not taking part

  • Earlier anti-cancer treatment for AML or MDS
  • Another cancer that needs anti-cancer treatment at the same time (hormonal therapy is allowed)
  • Currently getting cytarabine treatment other than up to 1 g/m^2 for urgent cytoreduction
  • Unwilling to give bone marrow and blood samples for research

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS
  • Participants must be >= 18 years of age
  • Participants must not have received prior anti-cancer therapy for AML or MDS; Note: Hydroxyurea to control the white blood cell count (WBC) is allowed; Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction
  • Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure; Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment
  • Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy; Note: active hormonal therapy is allowed
  • Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration
  • Participants must agree to have translational medicine specimens submitted
  • Participants must be offered the opportunity to participate in specimen banking; Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP
  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines; Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
  • The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to

Where in Puerto Rico

Also in 2 other countries, 358 sites

  • Centro Comprensivo de Cancer de UPRSan Juan, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Taking people
  • San Juan City HospitalSan Juan, Puerto RicoContact: Luis J. Santos Reyes (principal investigator)Taking people

About the trial

What the trial wants to find out

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

The 30 groups in the trial

  • MM1MDS-A01 Regimen 1 (ASTX727)Existing treatment, for comparison

    Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, and Decitabine and Cedazuridine

  • MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)Treatment being tested

    Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, and Enasidenib

  • MM1MDS-CTG02 Arm 1 (Luspatercept)Treatment being tested

    Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, and Luspatercept

  • MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)Treatment being tested

    Patients receive luspatercept SC on day 1 and epoetin alfa SC QW for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Epoetin Alfa, and Luspatercept

  • MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)Treatment being tested

    Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Emavusertib, and Luspatercept

  • MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)Treatment being tested

    INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial.

    Treatment: Azacitidine, Biopsy Procedure, Biospecimen Collection, and Venetoclax

  • MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)Treatment being tested

    INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial.

    Treatment: Azacitidine, Biopsy Procedure, Biospecimen Collection, Gilteritinib, and Venetoclax

  • MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)Treatment being tested

    INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial.

    Treatment: Azacitidine, Biopsy Procedure, Biospecimen Collection, Gilteritinib, and Venetoclax

  • MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)Existing treatment, for comparison

    Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, and Venetoclax

  • MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)Treatment being tested

    Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Olutasidenib, and Venetoclax

  • MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)Treatment being tested

    Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, and Olutasidenib

  • MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)Existing treatment, for comparison

    Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, and Decitabine and Cedazuridine

  • MM1OA-MDS-A05 Cohort C (olutasidenib)Treatment being tested

    Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, and Olutasidenib

  • MM1OA-S03 Arm 1 (ASTX727, venetoclax)Existing treatment, for comparison

    Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, and Venetoclax

  • MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)Treatment being tested

    Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib, and Venetoclax

  • MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)Existing treatment, for comparison

    Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine, and Venetoclax

  • MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)Treatment being tested

    Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine, and Venetoclax

  • MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)Existing treatment, for comparison

    Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.

    Treatment: Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Gemtuzumab Ozogamicin, and Multigated Acquisition Scan

  • MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)Treatment being tested

    Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.

    Treatment: Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, and Venetoclax

  • MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)Treatment being tested

    Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, and Venetoclax

  • MM1YA-CTG01 Arm II (azacitidine, venetoclax)Treatment being tested

    Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

    Treatment: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Echocardiography Test, Multigated Acquisition Scan, and Venetoclax

  • MM1YA-CTG01 Arm III (daunorubicin, cytarabine)Existing treatment, for comparison

    Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, and Multigated Acquisition Scan

  • MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)Treatment being tested

    See Detailed Description.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Daunorubicin, Echocardiography Test, Multigated Acquisition Scan, and Quizartinib

  • MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)Treatment being tested

    See Detailed Description.

    Treatment: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, Quizartinib, and Venetoclax

  • MM1YA-S01 Arm I (cytarabine, daunorubicin)Existing treatment, for comparison

    Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, and Multigated Acquisition Scan

  • MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)Treatment being tested

    Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, and Venetoclax

  • MM1YA-S01 Arm III (azacitidine, venetoclax)Treatment being tested

    Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

    Treatment: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Echocardiography Test, Multigated Acquisition Scan, and Venetoclax

  • MM1YA-S01 Arm IV (Vyxeos)Treatment being tested

    Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, and Multigated Acquisition Scan

  • MM1YA-S01 Arm V (Vyxeos, venetoclax)Treatment being tested

    Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.

    Treatment: Biospecimen Collection, Bone Marrow Aspiration, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, and Venetoclax

  • MM2YA-EA01 Arm A (cytarabine)Existing treatment, for comparison

    Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.

    Treatment: Biopsy Procedure, Cytarabine, Echocardiography Test, and Multigated Acquisition Scan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Plain-language title
Blood and marrow marker tests in acute myeloid leukemia and myelodysplastic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
2 November 2026